296. 胆道閉鎖症 Biliary atresia Clinical trials / Disease details
臨床試験数 : 71 / 薬物数 : 70 - (DrugBank : 39) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 60
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031210066 | 06/05/2021 | 06/05/2021 | bezafibrate for post operated bilirary atresia | Prospective study of bezafibrate for post operated bilirary atresia | Biliary Atresia Obstructive jaundice;D001656 | Bezafibrate 400 mg/day is orally administered to patients after biliary atresia in two divided doses after breakfast and dinner. | Terui Keita | NULL | Recruiting | >= 18age old | < 80age old | Both | 10 | Phase 2 | Japan |